Trial Profile
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms FUTURE 1 ext
- Sponsors Novartis; Novartis Pharmaceuticals
- 15 Jun 2019 Final five years results presented at the 20th Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Final 5-year efficacy and safety results, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 16 Oct 2018 According to a Novartis media release, data from the study, will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.